The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. We have more ideas, we see more opportunities and we want to help more patients.

Products, services, technology

We have four phase 3 products: daridorexant (insomnia), clazosentan (treatment of vasospasm following a sub-arachnoid subarachnoid hemorrhage), aprocitentan (difficult to treat hypertension) and lucerastat (Fabry's disease). Our pipeline has 12 assets in total.

Facts & figures
  • Type of organization
    Public company
  • Year of foundation
  • Number of employees in Switzerland
Key business

You may also be interested in